Merck/Pfizer's Latest SGLT-2 Data Support Attractive Ertugliflozin/Januvia Combo
Overall, data suggest a profile similar to J&J's market-leading Invokana, but analysts still see room for a new entrant to the anti-SGLT-2 class in type 2 diabetes.
You may also be interested in...
Merck’s focus has shifted increasingly to Keytruda and immuno-oncology, while the company’s older stalwarts like Zetia, Vytorin and Januvia face pressure.
FDA strengthens warning about risk of acute kidney injury for two SGLT2 inhibitors but not Jardiance, the only diabetes drug with data on cardiovascular benefit.
Merck & Co. Inc. and Pfizer Inc.'s investigational oral SGLT-2 inhibitor, ertugliflozin, has met its primary endpoints in two Phase III studies in type 2 diabetes patients – now the pair are continuing development with an 8,000 patient cardiovascular (CV) outcomes trial and plan to file the drug in US by the year end.